¹¹ | Íàèìåíîâàíèå | Ïðîèçâîäèòåëü | Öåíà â ðóá. ñ ÍÄÑ | Ïîñòàâùèê |
---|
|
1 | ÊÀËÜÖÈÉ-Ä3 òàáëåòêè 500ìã õ70 ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | Ðîññèÿ | Âíåøòîðãôàðìà | Íåäîñòóïíî | ÑÒÌÔàðì |
2 | ÊÀËÜÖÈÉ-Ä3 òàáëåòêè 500ìã õ70 ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | Ðîññèÿ | Âíåøòîðãôàðìà | Íåäîñòóïíî | Ìàãíèò Ôàðìà Àðõàíãåëüñê |
3 | ÊÀËÜÖÈÉ-Ä3 òàáëåòêè 500ìã õ70 ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | Ðîññèÿ | Âíåøòîðãôàðìà | Íåäîñòóïíî | Ìàãíèò Ôàðìà Íîâîñèáèðñê |
4 | ÊÀËÜÖÈÉ-Ä3 òàáëåòêè 500ìã õ70 ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | Ðîññèÿ | Âíåøòîðãôàðìà | Íåäîñòóïíî | Ìàãíèò Ôàðìà Ñàíêò-Ïåòåðáóðã |
5 | ÊÀËÜÖÈÉ-Ä3 òàáëåòêè 500ìã õ70 ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | Ðîññèÿ | Âíåøòîðãôàðìà | Íåäîñòóïíî | Ìàãíèò Ôàðìà |
6 | ÊÀËÜÖÈÉ-Ä3 òàáëåòêè 500ìã õ70 ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | Ðîññèÿ | Âíåøòîðãôàðìà | Íåäîñòóïíî | Ìàãíèò Ôàðìà Êðàñíîäàð |
7 | ÊÀËÜÖÈÉ-Ä3 òàáëåòêè 500ìã õ70 ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | Ðîññèÿ | Âíåøòîðãôàðìà | Íåäîñòóïíî | Ìàãíèò Ôàðìà Êàçàíü |
8 | ÊÀËÜÖÈÉ-Ä3 òàáëåòêè 500ìã õ70 ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | Ðîññèÿ | Âíåøòîðãôàðìà | Íåäîñòóïíî | Ìåäèëîí-Ôàðìèìýêñ |
9 | ÊÀËÜÖÈÉ-Ä3 òàáëåòêè õ100 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | Ðîññèÿ | Â-ÌÈÍ | Íåäîñòóïíî | Ìåäýêñïîðò - Ñåâåðíàÿ Çâåçäà |
10 | ÊÀËÜÖÈÉ-Ä3 òàáëåòêè õ100 ìàëèíà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | Ðîññèÿ | Â-ÌÈÍ | Íåäîñòóïíî | Ìåäýêñïîðò - Ñåâåðíàÿ Çâåçäà |
11 | ÊÀËÜÖÈÉ-Ä3 òàáëåòêè õ30 ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | Ðîññèÿ | Âíåøòîðãôàðìà | Íåäîñòóïíî | Ãðàíä Êàïèòàë Ñìîëåíñê |
12 | ÊÀËÜÖÈÉ-Ä3 òàáëåòêè õ30 ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | Ðîññèÿ | Âíåøòîðãôàðìà | Íåäîñòóïíî | Ãðàíä Êàïèòàë ÑÏá |
13 | ÊÀËÜÖÈÉ-Ä3 òàáëåòêè õ30 ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | Ðîññèÿ | Âíåøòîðãôàðìà | Íåäîñòóïíî | Ãðàíä Êàïèòàë Íîâîñèáèðñê |
14 | ÊÀËÜÖÈÉ-Ä3 òàáëåòêè õ30 ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | Ðîññèÿ | Âíåøòîðãôàðìà | Íåäîñòóïíî | Ãðàíä Êàïèòàë |
15 | ÊÀËÜÖÈÉ-Ä3 òàáëåòêè õ30 ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | Ðîññèÿ | Âíåøòîðãôàðìà | Íåäîñòóïíî | Ãðàíä Êàïèòàë Êèðîâ |
16 | ÊÀËÜÖÈÉ-Ä3 òàáëåòêè õ30 ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | Ðîññèÿ | Âíåøòîðãôàðìà | Íåäîñòóïíî | Ãðàíä Êàïèòàë Êðàñíîäàð |
17 | ÊÀËÜÖÈÉ-Ä3 òàáëåòêè õ30 ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | Ðîññèÿ | Âíåøòîðãôàðìà | Íåäîñòóïíî | Ãðàíä Êàïèòàë ×åáîêñàðû |
18 | ÊÀËÜÖÈÉ-Ä3 òàáëåòêè õ30 ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | Ðîññèÿ | Âíåøòîðãôàðìà | Íåäîñòóïíî | Ãðàíä Êàïèòàë Âîðîíåæ |
19 | ÊÀËÜÖÈÉ-Ä3 òàáëåòêè õ30 ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | Ðîññèÿ | Âíåøòîðãôàðìà | Íåäîñòóïíî | Ãðàíä Êàïèòàë Âîëãîãðàä |
20 | ÊÀËÜÖÈÉ-Ä3 òàáëåòêè õ30 ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | Ðîññèÿ | Âíåøòîðãôàðìà | Íåäîñòóïíî | Ãîäîâàëîâ |
21 | ÊÀËÜÖÈÉ-Ä3 òàáëåòêè õ50 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | Ðîññèÿ | Â-ÌÈÍ | Íåäîñòóïíî | Ìåäýêñïîðò - Ñåâåðíàÿ Çâåçäà |
22 | ÊÀËÜÖÈÉ-Ä3 òàáëåòêè õ50 ìàëèíà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | Ðîññèÿ | Â-ÌÈÍ | Íåäîñòóïíî | Ìåäýêñïîðò - Ñåâåðíàÿ Çâåçäà |
23 | ÊÀËÜÖÈÉ-Ä3 òàáëåòêè õ60 ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | Ðîññèÿ | Âíåøòîðãôàðìà | Íåäîñòóïíî | ÎëüÃîð |
24 | ÊÀËÜÖÈÉ-Ä3 ÂÈÒÀÌÈÐ òàáëåòêè õ100 àïåëüñèí | Ðîññèÿ | Êâàäðàò Ñ | Íåäîñòóïíî | Ãîäîâàëîâ |
25 | ÊÀËÜÖÈÉ-Ä3 ÄËß ÄÅÒÅÉ òàáëåòêè õ18 àïåëüñèí | Ðîññèÿ | Êâàäðàò Ñ | Íåäîñòóïíî | Ìåäýêñïîðò - Ñåâåðíàÿ Çâåçäà |
26 | ÊÀËÜÖÈÉ-Ä3 ÌÈÎÔÀÐÌ òàáëåòêè 2,2ã õ62 | Ðîññèÿ | Â-ÌÈÍ | Íåäîñòóïíî | ÁÑÑ-Êàçàíü |
27 | ÊÀËÜÖÈÉ-Ä3 ÌÈÎÔÀÐÌ òàáëåòêè 2,2ã õ62 | Ðîññèÿ | Â-ÌÈÍ | Íåäîñòóïíî | ÁÑÑ-Áðÿíñê |
28 | ÊÀËÜÖÈÉ-Ä3 ÌÈÎÔÀÐÌ òàáëåòêè 2,2ã õ62 | Ðîññèÿ | Â-ÌÈÍ | Íåäîñòóïíî | ÁÑÑ-Àñòðàõàíü |
29 | ÊÀËÜÖÈÉ-Ä3 ÌÈÎÔÀÐÌ òàáëåòêè 2,2ã õ62 | Ðîññèÿ | Â-ÌÈÍ | Íåäîñòóïíî | ÁÑÑ-Êîñòðîìà |
30 | ÊÀËÜÖÈÉ-Ä3 ÌÈÎÔÀÐÌ òàáëåòêè 2,2ã õ62 | Ðîññèÿ | Â-ÌÈÍ | Íåäîñòóïíî | ÁÑÑ-Îðåíáóðã |
31 | ÊÀËÜÖÈÉ-Ä3 ÌÈÎÔÀÐÌ òàáëåòêè 2,2ã õ62 | Ðîññèÿ | Â-ÌÈÍ | Íåäîñòóïíî | Ãðàíä Êàïèòàë Âîðîíåæ |
32 | ÊÀËÜÖÈÉ-Ä3 ÌÈÎÔÀÐÌ òàáëåòêè 2,2ã õ62 | Ðîññèÿ | Â-ÌÈÍ | Íåäîñòóïíî | Çäðàâñåðâèñ |
33 | ÊÀËÜÖÈÉ-Ä3 ÌÈÎÔÀÐÌ òàáëåòêè 2,2ã õ62 | Ðîññèÿ | Â-ÌÈÍ | Íåäîñòóïíî | Ðóññêàÿ Òðîéêà |
34 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ100 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Ñàìàðà |
35 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ñôåðà ÒÄ |
36 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Êàçàíü |
37 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìåä÷åñòà-Ì |
38 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Áðÿíñê |
39 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ôàðìèìýêñ-Êðàñíîäàð |
40 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Îáëàñòíîé àïòå÷íûé ñêëàä(ÎÀÑ) |
41 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àñòè Ïëþñ Âîëãîãðàä |
42 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÂÈÒÒÀ êîìïàíè |
43 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ðóññêàÿ Òðîéêà |
44 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Êðàñíîäàð |
45 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìåäà-Ô |
46 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Çäðàâñåðâèñ |
47 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àãðîðåñóðñû Íèæíèé Íîâãîðîä |
48 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÎëüÃîð |
49 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Âîëãîãðàä |
50 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë |
51 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Êàçàíü |
52 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àãðîðåñóðñû Òþìåíü |
53 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àñòè Íîâîñèáèðñê |
54 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Ñèìôåðîïîëü |
55 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Àñòðàõàíü |
56 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Õåëñ - Âîëîãäà |
57 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Âîðîíåæ |
58 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Êîñòðîìà |
59 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àãðîðåñóðñû Óôà |
60 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÌåäÒåõÍîâàöèè |
61 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Íîâîñèáèðñê |
62 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Êèðîâ |
63 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ôàðìêîìïëåêò |
64 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Þã-Ôàðì |
65 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Þã-Ôàðì |
66 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë ×åáîêñàðû |
67 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë ÑÏá |
68 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãîäîâàëîâ |
69 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Êðàñíîäàð |
70 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Ñìîëåíñê |
71 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Íàäåæäà-Ôàðì Õàáàðîâñê |
72 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Ñàíêò-Ïåòåðáóðã |
73 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ôàðìèíòîðã-ÎÏÒ |
74 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Ñàìàðà |
75 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Êàçàíü |
76 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Ìîñêâà |
77 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Ñàíêò-Ïåòåðáóðã |
78 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ôàðìèìýêñ Êàëèíèíãðàä |
79 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Åêàòåðèíáóðã |
80 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÌåäèàÌåä |
81 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Êîìïàíèÿ Îðãàíèêà-Þã |
82 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ËÅÑÀÍ ôàðìà Êðàñíîäàð |
83 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Íèæåãîðîäñêàÿ Îáëàñòíàÿ Ôàðìàöèÿ - ÍÎÔ |
84 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìåäèëîí-Ôàðìèìýêñ |
85 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àãðîðåñóðñû |
86 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ïðèáîé - Ðîñòîâ íà Äîíó |
87 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àãðîðåñóðñû Òþìåíü |
88 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Íîâîñèáèðñê |
89 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Ñàìàðà |
90 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Ñàíêò-Ïåòåðáóðã |
91 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Êðàñíîäàð |
92 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Àðõàíãåëüñê |
93 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Êàçàíü |
94 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ðóññêàÿ Òðîéêà |
95 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Çäðàâñåðâèñ |
96 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àñòè Ïëþñ Âîëãîãðàä |
97 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÏðîôèòÌåä ÑïÁ |
98 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Õåëñ - Âîëîãäà |
99 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Íîâàÿ Áîëüíèöà ÌÎ |
100 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÎëüÃîð |
101 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë |
102 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë ×åáîêñàðû |
103 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÀêöåíòÌåä Ìîñêâà |
104 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àñòè Íîâîñèáèðñê |
105 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ðóññêàÿ Òðîéêà |
106 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÀÑÒÈ Ôàðìàöåâòèêà |
107 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Âîðîíåæ |
108 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Êèðîâ |
109 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Âîëãîãðàä |
110 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Íîâîñèáèðñê |
111 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë ÑÏá |
112 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÌåäÒåõÍîâàöèè |
113 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Íàäåæäà-Ôàðì Õàáàðîâñê |
114 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ôàðìêîìïëåêò |
115 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Êðàñíîäàð |
116 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Ñìîëåíñê |
117 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Íàäåæäà-Ôàðì Õàáàðîâñê |
118 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ËÅÑÀÍ ôàðìà Êðàñíîäàð |
119 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ËÅÑÀÍ Ôàðìà Êðûì |
120 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ïðèáîé - Ðîñòîâ íà Äîíó |
121 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ñîëåêñ |
122 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ôàðìáèî |
123 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÈíòåðËåê |
124 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÌåäÒåõÍîâàöèè |
125 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Íîâîñèáèðñê |
126 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Çäðàâñåðâèñ |
127 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Îðåíáóðã |
128 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ñôåðà ÒÄ |
129 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Êàçàíü |
130 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÎëüÃîð |
131 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Àðõàíãåëüñê |
132 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Ñàíêò-Ïåòåðáóðã |
133 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Áðÿíñê |
134 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Êàçàíü |
135 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àñòè Ïëþñ Âîëãîãðàä |
136 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÈíòåðËåê |
137 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Ñèìôåðîïîëü |
138 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Êðàñíîäàð |
139 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àãðîðåñóðñû Òþìåíü |
140 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Àñòðàõàíü |
|
141 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àãðîðåñóðñû Íèæíèé Íîâãîðîä |
142 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àãðîðåñóðñû Óôà |
143 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÀÑÒÈ Ôàðìàöåâòèêà |
144 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Õåëñ - Âîëîãäà |
145 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÀêöåíòÌåä Ìîñêâà |
146 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ðåãèîí |
147 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Âîðîíåæ |
148 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àñòè Íîâîñèáèðñê |
149 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë ÑÏá |
150 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë ×åáîêñàðû |
151 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë |
152 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÏðîôèòÌåä ÑïÁ |
153 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Íîâîñèáèðñê |
154 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Êðàñíîäàð |
155 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Âîëãîãðàä |
156 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Êèðîâ |
157 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ôàðìêîìïëåêò |
158 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ðóññêàÿ Òðîéêà |
159 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÏðîôèòÌåä |
160 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Ñìîëåíñê |
161 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ôàðìèíòîðã-ÎÏÒ |
162 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ôàðìèíòîðã-ÎÏÒ |
163 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Íàäåæäà-Ôàðì Õàáàðîâñê |
164 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Êîìïàíèÿ Îðãàíèêà-Þã |
165 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Þã-Ôàðì |
166 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ËÅÑÀÍ ôàðìà Êðàñíîäàð |
167 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ËÅÑÀÍ Ôàðìà Êðûì |
168 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ120 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àãðîðåñóðñû |
169 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ñôåðà ÒÄ |
170 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Àðõàíãåëüñê |
171 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ôàðìèìýêñ-Êðàñíîäàð |
172 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ðóññêàÿ Òðîéêà |
173 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Õåëñ - Âîëîãäà |
174 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÀÑÒÈ Ôàðìàöåâòèêà |
175 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Çäðàâñåðâèñ |
176 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Ñèìôåðîïîëü |
177 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àñòè Ïëþñ Âîëãîãðàä |
178 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÎëüÃîð |
179 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àãðîðåñóðñû Òþìåíü |
180 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Êàçàíü |
181 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àãðîðåñóðñû Íèæíèé Íîâãîðîä |
182 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ðåãèîí |
183 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìåä÷åñòà-Ì |
184 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Áðÿíñê |
185 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Âîðîíåæ |
186 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ñîëåêñ |
187 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Àñòðàõàíü |
188 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë |
189 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÀêöåíòÌåä Ìîñêâà |
190 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àñòè Íîâîñèáèðñê |
191 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÌåäÒåõÍîâàöèè |
192 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãîäîâàëîâ |
193 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Íîâîñèáèðñê |
194 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Ñàìàðà |
195 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Ñàíêò-Ïåòåðáóðã |
196 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Êàçàíü |
197 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Êðàñíîäàð |
198 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Âîëãîãðàä |
199 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë ×åáîêñàðû |
200 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Êðàñíîäàð |
201 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ôàðìêîìïëåêò |
202 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë ÑÏá |
203 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Êèðîâ |
204 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Åêàòåðèíáóðã |
205 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Íîâîñèáèðñê |
206 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Ñìîëåíñê |
207 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Îðåíáóðã |
208 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ôàðìèìýêñ Êàëèíèíãðàä |
209 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Þã-Ôàðì |
210 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ôàðìèíòîðã-ÎÏÒ |
211 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÌåäèàÌåä |
212 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ËÅÑÀÍ ôàðìà Êðàñíîäàð |
213 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ËÅÑÀÍ Ôàðìà Êðûì |
214 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìåäèëîí-Ôàðìèìýêñ |
215 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 àïåëüñèí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àãðîðåñóðñû |
216 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Äæè Äè Ïè |
217 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ñôåðà ÒÄ |
218 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìåä÷åñòà-Ì |
219 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÀÑÒÈ Ôàðìàöåâòèêà |
220 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Ñàíêò-Ïåòåðáóðã |
221 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àñòè Ïëþñ Âîëãîãðàä |
222 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ðóññêàÿ Òðîéêà |
223 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Àñòðàõàíü |
224 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Íîâîñèáèðñê |
225 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Êàçàíü |
226 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Êàçàíü |
227 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Àðõàíãåëüñê |
228 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Ñàíêò-Ïåòåðáóðã |
229 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Êîñòðîìà |
230 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÏðîôèòÌåä ÑïÁ |
231 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÀêöåíòÌåä Ìîñêâà |
232 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Çäðàâñåðâèñ |
233 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Êðàñíîäàð |
234 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìåäà-Ô |
235 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÈíòåðËåê |
236 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Êàçàíü |
237 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ñîëåêñ |
238 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Çäðàâñåðâèñ |
239 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Õåëñ - Âîëîãäà |
240 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Âîðîíåæ |
241 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÎëüÃîð |
242 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ðóññêàÿ Òðîéêà |
243 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ôàðìêîìïëåêò |
244 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãîäîâàëîâ |
245 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë |
246 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Íîâîñèáèðñê |
247 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Áðÿíñê |
248 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë ÑÏá |
249 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÌåäÒåõÍîâàöèè |
250 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Êðàñíîäàð |
251 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Þã-Ôàðì |
252 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë ×åáîêñàðû |
253 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Êèðîâ |
254 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Ñìîëåíñê |
255 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Âîëãîãðàä |
256 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ôàðìèíòîðã-ÎÏÒ |
257 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àãðîðåñóðñû Íèæíèé Íîâãîðîä |
258 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àãðîðåñóðñû Òþìåíü |
259 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ôàðìèìýêñ Êàëèíèíãðàä |
260 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Íàäåæäà-Ôàðì Õàáàðîâñê |
261 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Êîìïàíèÿ Îðãàíèêà-Þã |
262 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Ñàìàðà |
263 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ËÅÑÀÍ ôàðìà Êðàñíîäàð |
264 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ËÅÑÀÍ Ôàðìà Êðûì |
265 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Ñèìôåðîïîëü |
266 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Ìîñêâà |
267 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Ñàíêò-Ïåòåðáóðã |
268 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 êëóáíèêà-àðáóç ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìåäèëîí-Ôàðìèìýêñ |
269 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ôàðìèìýêñ-Êðàñíîäàð |
270 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ñôåðà ÒÄ |
271 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Íîâîñèáèðñê |
272 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Ñàíêò-Ïåòåðáóðã |
273 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Àñòðàõàíü |
274 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àãðîðåñóðñû Òþìåíü |
275 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìåä÷åñòà-Ì |
276 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Áðÿíñê |
277 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Êàçàíü |
278 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ðóññêàÿ Òðîéêà |
279 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÀÑÒÈ Ôàðìàöåâòèêà |
280 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Êðàñíîäàð |
|
281 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Îáëàñòíîé àïòå÷íûé ñêëàä(ÎÀÑ) |
282 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Ñàìàðà |
283 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Êîñòðîìà |
284 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àñòè Ïëþñ Âîëãîãðàä |
285 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÈíòåðËåê |
286 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Àðõàíãåëüñê |
287 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Êàçàíü |
288 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Çäðàâñåðâèñ |
289 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÂÈÒÒÀ êîìïàíè |
290 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àñòè Íîâîñèáèðñê |
291 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÎëüÃîð |
292 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Õåëñ - Âîëîãäà |
293 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Âîðîíåæ |
294 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë ×åáîêñàðû |
295 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÌåäÒåõÍîâàöèè |
296 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãîäîâàëîâ |
297 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë ÑÏá |
298 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë |
299 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÀêöåíòÌåä Ìîñêâà |
300 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Íîâîñèáèðñê |
301 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Êðàñíîäàð |
302 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àãðîðåñóðñû Íèæíèé Íîâãîðîä |
303 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ôàðìêîìïëåêò |
304 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Âîëãîãðàä |
305 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Êèðîâ |
306 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Íàäåæäà-Ôàðì Õàáàðîâñê |
307 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Ñìîëåíñê |
308 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Îðåíáóðã |
309 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Åêàòåðèíáóðã |
310 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Êîìïàíèÿ Îðãàíèêà-Þã |
311 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Þã-Ôàðì |
312 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ËÅÑÀÍ ôàðìà Êðàñíîäàð |
313 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ôàðìèíòîðã-ÎÏÒ |
314 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ òàáëåòêè õ60 ìÿòà ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìåäèëîí-Ôàðìèìýêñ |
315 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àãðîðåñóðñû Òþìåíü |
316 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìåä÷åñòà-Ì |
317 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àãðîðåñóðñû Óôà |
318 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÌåäÒåõÍîâàöèè |
319 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ðóññêàÿ Òðîéêà |
320 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Êèðîâ |
321 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Íîâîñèáèðñê |
322 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Îðåíáóðã |
323 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Êðàñíîäàð |
324 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÈíòåðËåê |
325 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àñòè Ïëþñ Âîëãîãðàä |
326 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÀÑÒÈ Ôàðìàöåâòèêà |
327 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Åêàòåðèíáóðã |
328 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Ñèìôåðîïîëü |
329 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Âîðîíåæ |
330 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìåäà-Ô |
331 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Çäðàâñåðâèñ |
332 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Àñòðàõàíü |
333 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãîäîâàëîâ |
334 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Íîâîñèáèðñê |
335 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Àðõàíãåëüñê |
336 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Ñàìàðà |
337 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Ñàíêò-Ïåòåðáóðã |
338 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Êàçàíü |
339 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Êðàñíîäàð |
340 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë ×åáîêñàðû |
341 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë |
342 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë ÑÏá |
343 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àñòè Íîâîñèáèðñê |
344 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÀêöåíòÌåä Ìîñêâà |
345 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Âîëãîãðàä |
346 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Õåëñ - Âîëîãäà |
347 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÎëüÃîð |
348 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ôàðìêîìïëåêò |
349 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ôàðìèìýêñ-Êðàñíîäàð |
350 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Êîñòðîìà |
351 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àãðîðåñóðñû Íèæíèé Íîâãîðîä |
352 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Áðÿíñê |
353 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Êàçàíü |
354 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Íàäåæäà-Ôàðì Õàáàðîâñê |
355 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Ñìîëåíñê |
356 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ôàðìèíòîðã-ÎÏÒ |
357 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÌåäèàÌåä |
358 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ôàðìèìýêñ Êàëèíèíãðàä |
359 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Þã-Ôàðì |
360 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ËÅÑÀÍ ôàðìà Êðàñíîäàð |
361 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ËÅÑÀÍ Ôàðìà Êðûì |
362 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìåäèëîí-Ôàðìèìýêñ |
363 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ120 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ëåíìåäèíôîðì |
364 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Äæè Äè Ïè |
365 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ôàðìèìýêñ-Êðàñíîäàð |
366 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Êîñòðîìà |
367 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Îðåíáóðã |
368 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Ìîñêâà |
369 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Ñàíêò-Ïåòåðáóðã |
370 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Íîâîñèáèðñê |
371 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Íîâàÿ Áîëüíèöà ÌÎ |
372 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Íîâîñèáèðñê |
373 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Àñòðàõàíü |
374 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÀÑÒÈ Ôàðìàöåâòèêà |
375 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Ñàìàðà |
376 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Ñàíêò-Ïåòåðáóðã |
377 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Åêàòåðèíáóðã |
378 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àñòè Ïëþñ Âîëãîãðàä |
379 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Êàçàíü |
380 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Àðõàíãåëüñê |
381 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Êðàñíîäàð |
382 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Çäðàâñåðâèñ |
383 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìåäà-Ô |
384 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Ñèìôåðîïîëü |
385 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Êðàñíîäàð |
386 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÀêöåíòÌåä Ìîñêâà |
387 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àñòè Íîâîñèáèðñê |
388 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Âîëãîãðàä |
389 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë |
390 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Õåëñ - Âîëîãäà |
391 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Áðÿíñê |
392 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë ×åáîêñàðû |
393 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Êàçàíü |
394 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë ÑÏá |
395 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Âîðîíåæ |
396 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÎëüÃîð |
397 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Íîâîñèáèðñê |
398 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ôàðìêîìïëåêò |
399 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àãðîðåñóðñû Òþìåíü |
400 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Àãðîðåñóðñû Íèæíèé Íîâãîðîä |
401 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÌåäÒåõÍîâàöèè |
402 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ðóññêàÿ Òðîéêà |
403 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ÁÑÑ-Ðîñòîâ |
404 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ìàãíèò Ôàðìà Ñàíêò-Ïåòåðáóðã |
405 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Íàäåæäà-Ôàðì Õàáàðîâñê |
406 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Êèðîâ |
407 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ãðàíä Êàïèòàë Ñìîëåíñê |
408 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ôàðìèíòîðã-ÎÏÒ |
409 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Þã-Ôàðì |
410 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ñîëåêñ |
411 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ËÅÑÀÍ ôàðìà Êðàñíîäàð |
412 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | ËÅÑÀÍ Ôàðìà Êðûì |
413 | ÊÀËÜÖÈÉ-Ä3 ÍÈÊÎÌÅÄ ôîðòå òàáëåòêè õ60 ëèìîí ÌÍÍ: ÊÀËÜÖÈß ÊÀÐÁÎÍÀÒ, ÊÎËÅÊÀËÜÖÈÔÅÐÎË | | Takeda Pharmaceuticals | Íåäîñòóïíî | Ïðèáîé - Ðîñòîâ íà Äîíó |
414 | ÊÀËÜÖÈÉ-Ä3 Ñ ÂÈÒÀÌÈÍÀÌÈ êàïñóëû õ100 | Ðîññèÿ | Ëþìè | Íåäîñòóïíî | ÈíòåðËåê |
415 | ÊÀËÜÖÈÉ-Ä3 Ñ ÂÈÒÀÌÈÍÀÌÈ êàïñóëû õ100 | Ðîññèÿ | Ëþìè | Íåäîñòóïíî | Àãðîðåñóðñû Óôà |
416 | ÊÀËÜÖÈÉ-Ä3 Ñ ÂÈÒÀÌÈÍÀÌÈ êàïñóëû õ100 | Ðîññèÿ | Ëþìè | Íåäîñòóïíî | Àãðîðåñóðñû Íèæíèé Íîâãîðîä |
417 | ÊÀËÜÖÈÉ-Ä3 Ñ ÂÈÒÀÌÈÍÀÌÈ êàïñóëû õ100 | Ðîññèÿ | Ëþìè | Íåäîñòóïíî | Àãðîðåñóðñû Òþìåíü |
418 | ÊÀËÜÖÈÉ-Ä3 Ñ ÂÈÒÀÌÈÍÀÌÈ êàïñóëû õ100 | Ðîññèÿ | Ëþìè | Íåäîñòóïíî | Àãðîðåñóðñû |
419 | ÊÀËÜÖÈÉ-Ä3 ÔÎÐÒÅ òàáëåòêè õ120 ÷åðíèêà | Ðîññèÿ | Â-ÌÈÍ | Íåäîñòóïíî | Ìåäýêñïîðò - Ñåâåðíàÿ Çâåçäà |
420 | ÊÀËÜÖÈÉ-Ä3-ÌÈÊ êàïñóëû 66,7ÌÅ/166,7ìã õ60 | Áåëàðóñü | Ìèíñêèíòåðêàïñ | Íåäîñòóïíî | Ìèíñêèíòåðêàïñ |